CYP3A4 and acute myeloid leukemia: Here, we find that BMSC CYP3A4 and CDA are not only influenced by the status of the AML and its treatment, but clinically targeting drug metabolizing enzymes in the microenvironment also holds promise in modulating the adverse effects of MRD on extrinsic drug resistance.